Press Releases Can-Fite BioPharma Ltd. Nyse

Equities

CANF

US13471N1028

End-of-day quote Nyse Other stock markets 04:30:00 05/02/2024 am IST			5-day change	1st Jan Change
2.02 ^USD	-3.35%		-4.04%	-8.18%

24/06	Can-Fite Announces Breakthrough Findings Demonstrate Namodenoson Anti-Cancer and Protective Effect Mechanism in the Liver	CI
10/06	Can-Fite Biopharma Ltd. Receives IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Can Fite BioPharma : Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver	24/06	PU
Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver	24/06	BU
Can Fite BioPharma : Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study	10/06	PU
Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study	10/06	BU
Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study	05/06	BU
Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases	29/05	BU
Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024	27/05	BU
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6	23/05	BU
Can Fite BioPharma : Immediate Report of Meeting	23/05	PU
Can Fite BioPharma : NOTICE OF 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS - Form 6-K	23/05	PU
Can Fite BioPharma : Immediate Report	13/05	PU
Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study	13/05	BU
CAN-FITE, FDA GRANTS IND CLEARANCE FOR NAMODENOSON TO TREAT MASH PATIENTS IN A PHASE IIB STUDY	10/05	AQ
Can Fite BioPharma : FDA grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study	09/05	PU
Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study	09/05	BU
Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602	06/05	BU
LONG-TERM COMPLETE RESPONSE TO CAN-FITE'S NAMODENOSON IN PATIENT WITH ADVANCED LIVER CANCER ARTICLE PUBLISHED IN A LEADING SCIENTIFIC JOURNAL	26/04	AQ
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal	25/04	BU
CAN-FITE, SCIENTIFIC ARTICLE PUBLISHED BY KOL PRESENTS NAMODENOSON AS A PROMISING DRUG CANDIDATE TO TREAT ADVANCED LIVER CANCER AND MASH	16/04	AQ
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH	15/04	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Can-Fite BioPharma Ltd. Nyse

Equities

CANF

US13471N1028

Press Releases

Filters